期刊文献+

高通量血液透析治疗老年肾性骨病患者的临床研究

Treating elderly renal osteodystrophy by high throughput hemodialysis
下载PDF
导出
摘要 目的:研究高通量血液透析治疗老年肾性骨病患者的临床疗效。方法:选定本院收治的100例老年肾性骨病(Renal Osteodystropl,ROD)患者,研究时段为2017年2-12月,在随机数字表法的分组原则下,分为研究组(50例,高通量血液透析)、对照组(50例,普通低通量透析),比较临床指标、治疗效果。结果:研究组β2-微球蛋白、磷显著较对照组低,钙、临床总有效率显著较对照组高,P<0.05。结论:高通量血液透析可有效改善老年ROD患者病情,提高血钙水平,效果显著,值得借鉴。 Objective:To study clinical efficacy of high throughput hemodialysis on elderly renal osteodystrophy.Methods:100 cases were divided into two groups,50 cases in each.The control group was given low flux hemodialysis;and the study group was given high throughput hemodialysis.Results:The β2-microglobulin and phosphorus in the study group were significantly lower than the control group;calcium and clinical total efficiency were significantly higher than the control group,P<0.05.Conclusion:High throughput hemodialysis on elderly renal osteodystrophy shows a good effect,increase blood calcium levels,and is worthy of promotion.
作者 梁戈 Liang Ge
机构地区 茂名市人民医院
出处 《中医临床研究》 2019年第10期141-142,共2页 Clinical Journal Of Chinese Medicine
关键词 高通量血液透析 肾性骨病 临床疗效 Highthroughput hemodialysis Renal osteodystrophy Clinical efficacy
  • 相关文献

二级参考文献65

  • 1Goodman WG,Goldin J,Kuizon BD. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis[J].{H}New England Journal of Medicine,2000,(20):1478-1483.
  • 2Nickolas TL,Stein E,Cohen A. Bone mass and microarchitecture in CKD patients with fracture[J].{H}Journal of the American Society of Nephrology,2010,(8):1371-1380.
  • 3Cantor T,Sci B. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay[J].{H}NEFROLOGIA,2003,(Suppl 2):S69-S72.
  • 4Kestenbaum B, Beloozeroff V. Mineral metabolism disturbances in patients with chronic kieney disease[J]. European J clinical Investigation,2007,37(8) : 607-622.
  • 5Zou Ms, Yu J, Nie Gin, et al. 1,25-dihydroxyvitamin D3 deerea- ses adriamyein-induced podoeyte apoptosls and loss[J]. Int J Med Sci,2010,7(5) :290-299.
  • 6Gurierrez O,lsakova T,Rhee E, et al. Fihroblast growth factor 23 mitigates hyperphosphatemia hut accentuates calcitriol deft- ciencyin chronic kidney disease[J]. J Am Soc Nephrol, 2005,16 : 2205-2215.
  • 7Negri AL. Fibrohlast growth factor 23:associations with cardio- vascular disease and mortality in chronic kidney disease[J]. Int Urol Nephrol, 2013, I 0 : 1147-115.
  • 8Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.Kidney Int 2,2011,79 : 1370-1378.
  • 9Taylor EN ,Rimm EB ,Stampfer MJ,et al. Plasma fibroblast growth.factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J,2011,161:956-962.
  • 10Kurosu H,Ogawa Y,Miyoshi M ,et al. Regulation of fibre blast growth factor-23 signaling by klotho[J]. J Biol Chem ,2006,281 : 6120-6123.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部